Answers are grounded in this paper and cite their sources.
This study evaluated the performance of MAP Wound Matrix, a flowable microporous annealed particle (MAP) hydrogel, for the treatment of full‐thickness cutaneous wounds in a porcine model. The MAP Wound Matrix device was compared to OASIS Ultra Tri‐Layer Matrix and Aquaphor as comparator and control treatments, respectively. Wound healing progression was assessed clinically and histologically over a 35‐day period. Clinical assessments included gross wound area reduction (i.e., wound contraction), mean time to wound closure, erythema, and edema. Histopathologic analysis evaluated inflammation, re‐epithelialization, granulation tissue formation, and device degradation. MAP Wound Matrix‐treated wounds exhibited early tissue integration with minimal inflammation and near‐complete device degradation by Day 21, consistent with a non‐irritant tissue response. By Day 14, MAP‐treated wounds showed substantially greater epithelial coverage than Oasis and similar coverage to Aquaphor. By Day 21, all treatments reached the highest re‐epithelialization score (> 75%), indicating no delay in epithelial resurfacing with MAP. These findings demonstrate that MAP Wound Matrix supports timely wound healing with a favorable local tissue response and resolution of inflammation by Day 21 in this large‐animal model.
No takes yet. Share an insight, caveat, or question.
Roosa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: